Envisagenics
Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Their breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs. Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory.
Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Their breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs. Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory.
Envisagenics has raised $27.0M across 2 rounds. Its most recent round was a Series B of $25.0M in Jun 2024. Full funding history, investors, and team are detailed below.
Funding history
2 rounds on record — latest round shown, the rest unlock with a paid plan.
Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Envisagenics is featured in
Similar companies
Verisoul is a company that designs a decentralized platform with artificial intelligence, aiming to aid businesses in combating the presence of fraudulent users. By merging anonymity and accountability, Verisoul collaborates with Web3 developers to enable them in identifying reliable users while distinguishing them from scammers, bots, and imposters.
Model ML is an AI tool that improves workflows for investment banks and private equity firms by integrating multiple data sources for research and due diligence, with the goal of revolutionizing the finance industry with a more efficient AI workspace.
Apptronik fabricates and plans human-focused mechanical technology frameworks.
Momentic allows developers to deploy AI agents to test the complete functionality of web applications by simply describing user flows in a natural language.
The company Harmonic creates Mathematical Superintelligence (MSI), a cutting-edge artificial intelligence system grounded in mathematical principles to ensure precision and eliminate errors.
Scale Social is an AI-powered marketing platform that automates capturing, curating, and distributing customer-generated content. It is specifically designed to help small businesses drive growth through authentic, high-impact digital marketing.
Federato's RiskOps underwriting platform for insurance carriers, MGAs and MGUs provides real-time risk selection and portfolio insights to empower underwriters to balance their book of business and make better underwriting decisions.
Kalshi is a financial exchange that is regulated by the government and allows investors to trade based on their predictions of future events. The markets offered by Kalshi cover various topics such as economics, international affairs, media, entertainment, climate, and public health. Unlike traditional instruments like stocks or bonds, Kalshi's markets are more specific, giving investors direct exposure to events and trends they are interested in. For example, a market on the signing of a free trade agreement can help retail investors gain exposure to emerging markets and changes in international trade. Check out their website at https://kalshi.com.
Suno is a music startup that allows individuals to create the music they desire, with the goal of helping people find pleasure in play and discovery once again.
Organizations trust Numeric to guarantee the accuracy of their financial information, streamline the month-end closing process, and provide immediate insights. With a rating of 4.9 out of 5 on G2.
AI Proteins is a biotechnology company that focuses on the design and engineering of synthetic mini protein therapeutics. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Luma is an AI company building the future of 3D.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.